Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT06915909

Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial

Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial — Recruiting • Non-phase study • Oncology • NCT06915909.

📅 08 Jul 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06915909
Sponsor
East and North Hertfordshire NHS Trust
Start
2025-04-22
ClinicaliQ Trial Snapshot
  • Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial — Recruiting • Non-phase study • Oncology • NCT06915909.
  • What is being tested: Feasibility of using artificial intelligence to review operative outcomes, specifically pain levels, when comparing two commonly used robotic surgical devices for prostate cancer removal.
  • Patient eligibility overview: The trial involves patients undergoing robotic-assisted laparoscopic prostatectomy (RALP) for prostate cancer treatment, comparing outcomes between the two surgical platforms used in standard clinical practice.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The 'Robotic Prostatectomy Artificial Intelligence Low Pressure Pain Study Trial' aims to assess the feasibility of being able to review operative outcomes such as pain when comparing two commonly used surgical devices for the removal of prostate cancers. The data collected will inform methodologies for future, larger, multi-center trials investigating pain in patients undergoing prostate cancer surgery. A robotic prostatectomy is a commonly performed surgery used to treat prostate cancer by removing the prostate gland. In order to perform the procedure, the surgeon must 'inflate' (technical term pneumoperitoneum) the patients…

Eligibility Snapshot
  • : * Patient indicated for non-emergent robotic Prostatectomy surgery * Patients (or appropriate legal representatives) able to provide written informed consent to participate in the study * Males, aged 18 to 75 years * Have no significant psychopathology that could limit the subject's ability to understand the procedure, comply with medical, surgical, and/or behavioural recommendations and office visits * Are American Society of Anaesthesiologists (ASA) Class I, II, or III);

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
Oncology · 16 Jul 2026
Evaluation terminated – NICE discontinued appraisal of lutetium-177 vipivotide tetraxetan; this agent is not recommended for routine NHS use and should not…
View guideline →
Guideline
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Oncology · 09 Jul 2026
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based…
View guideline →
Guideline
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Oncology · 16 Jun 2026
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering…
View guideline →
Clinical Brief
Advanced radiotherapy for prostate cancer to cut sessions from 20 to five
Oncology · BBC Health · 09 Jun 2026
Advanced hypofractionated radiotherapy for prostate cancer is now available on the NHS in England, reducing treatment from 20 sessions to 5 The…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →